SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50203FGEN - has AZN presented or talked about pricing in China? Seems like a big uncsemi_infinite -8/9/2018
50202Of course Dr Friedman said that MDGL could do the Ph3 trial themselves. RemembeBiotech Jim28/9/2018
50201Re: Lutathera as competitor. Could be, to a small extent. There have been a cotuck-8/8/2018
50200FGEN - PC Is Lutathera a competitor in PC? My brother in law thinks it could IRWIN JAMES FRANKEL-8/8/2018
50199On FGEN, best to ignore what the analysts say. They are mostly pretty clueless. Biomaven28/8/2018
50198FGEN: Does anyone know how long the lag from approval to commercial manufacturetuck-8/8/2018
50197Depends on your definition of "tad" :-)ghmm-8/8/2018
50196Isn't a year and a half from end of phase II to Phase III (IPF) a tad slow? JamesK-8/8/2018
50195madrigalpharma.com SL 36-39, and 40 indicate that 2 points reduction in F-scoreMiljenko Zuanic-8/8/2018
50194I believe scarring can be reversed if caught early enough. Question is where resemi_infinite -8/8/2018
50193<Scarring is just hard to reverse the more it progresses and that applies to Miljenko Zuanic-8/8/2018
5019257.1% F1 according to the spreadsheet linked below. Higher than NASH/CRN cohortsemi_infinite -8/8/2018
50191NBIX had an earnings conference call a couple of days ago that I though was goodA.J. Mullen-8/8/2018
50190Tuck, yes 50% F1 subjects in P2b is sticky point (IMO) and downplay "great&Miljenko Zuanic-8/8/2018
50189Would you add to FGEN holdings here based on their report? The stock was up aftCpi3663-8/8/2018
50188FGEN earnings transcript: seekingalpha.comA.J. Mullen-8/7/2018
50187I read the book and it is indeed very good. It will make your blood boil. It&#Biomaven-8/7/2018
50186My brief updates on FGEN call: twitter.comBiomaven38/7/2018
50185So apparently MDGL disclosed on the call that about 50% of the study population tuck-8/7/2018
50184Be very careful with Madrigal--very careful! The name Madrigal played a big partArthur Radley-8/7/2018
50183Being somewhat cynical of whatever GS presents in public, I wonder if the party(semi_infinite -8/7/2018
50182Re: Madrigal. The 36 week biopsy data showed a statistically significant, thougtuck-8/7/2018
50181Average hospital stay is 21 days, so what you posted makes sense. (That's agcrispin-8/6/2018
50180I have read that in vivo results in animals should translate well to humans, howteevee-8/5/2018
50179Two years ago my brother died from endcarditis. Essentially, the staph, I suspegcrispin-8/5/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News